Nantahala Capital discloses 5.68% Inhibikase (IKT) stake in 13G/A

Rhea-AI Filing Summary

Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack report their beneficial ownership of Inhibikase Therapeutics common stock on an amended Schedule 13G. As of December 31, 2025, they may be deemed to beneficially own 7,037,916 shares, or 5.68% of the outstanding common stock.

This total includes 3,108,624 shares that could be acquired within sixty days through warrant exercises. The reporting persons state they share voting and dispositive power over these shares and certify the holdings are in the ordinary course of business, not for the purpose of changing or influencing control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

INHIBIKASE THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

45719W205

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 45719W205

1

Names of Reporting Persons

Nantahala Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,037,916.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,037,916.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,037,916.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.68 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 45719W205

1

Names of Reporting Persons

Wilmot B. Harkey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,037,916.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,037,916.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,037,916.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.68 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 45719W205

1

Names of Reporting Persons

Daniel Mack

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,037,916.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,037,916.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,037,916.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.68 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: INHIBIKASE THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 1000 N. WEST STREET, SUITE 1200 WILMINGTON, DELAWARE, 19801
Item 2.
(a)	Name of person filing: (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
(b)	Address or principal business office or, if none, residence: 130 Main St. 2nd Floor, New Canaan, Connecticut 06840
(c)	Citizenship: (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 45719W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of December 31, 2025, Nantahala may be deemed to be the beneficial owner of 7,037,916 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 7,037,916 Shares includes 3,108,624 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
(b)	Percent of class: As of December 31, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 5.68% (2) Wilmot B. Harkey: 5.68% (3) Daniel Mack: 5.68%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(ii) Shared power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 7,037,916 Shares. (2) Wilmot B. Harkey: 7,037,916 Shares. (3) Daniel Mack: 7,037,916 Shares.
	(iii) Sole power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(iv) Shared power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 7,037,916 Shares. (2) Wilmot B. Harkey: 7,037,916 Shares. (3) Daniel Mack: 7,037,916 Shares.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nantahala Capital Management, LLC

Signature:	/s/ Taki Vasilakis
Name/Title:	Taki Vasilakis / Chief Compliance Officer
Date:	02/13/2026

Wilmot B. Harkey

Signature:	/s/ Wilmot B. Harkey
Name/Title:	Wilmot B. Harkey
Date:	02/13/2026

Daniel Mack

Signature:	/s/ Daniel Mack
Name/Title:	Daniel Mack
Date:	02/13/2026

FAQ

How much of Inhibikase Therapeutics (IKT) does Nantahala Capital report owning?

Nantahala Capital and its principals report beneficial ownership of 7,037,916 Inhibikase Therapeutics shares, equal to 5.68% of the company’s common stock as of December 31, 2025. This figure includes both currently held shares and shares underlying warrants exercisable within sixty days.

Who are the reporting persons in this Inhibikase Therapeutics (IKT) Schedule 13G/A?

The reporting persons are Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack. Nantahala is an investment adviser, and Messrs. Harkey and Mack, as its managing members, may be deemed beneficial owners of the same Inhibikase Therapeutics shares reported in the filing.

How many Inhibikase Therapeutics (IKT) shares can Nantahala acquire via warrants?

The reporting persons disclose that the 7,037,916 shares of Inhibikase beneficially owned include 3,108,624 shares that may be acquired within sixty days through the exercise of warrants. These warrant shares are counted in their reported beneficial ownership percentage of the common stock.

Do Nantahala and its principals have sole or shared voting power over IKT shares?

The filing states they have 0 shares with sole voting or dispositive power and 7,037,916 shares with shared voting and dispositive power. This means decisions on voting and disposition are made collectively regarding the reported Inhibikase Therapeutics shares, not individually.

What is the purpose of Nantahala’s Inhibikase Therapeutics (IKT) holdings under this Schedule 13G/A?

The reporting persons certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Inhibikase. They also state the holdings are not connected with any transaction aimed at obtaining such control.

What type of filing is this for Inhibikase Therapeutics (IKT) and what does Amendment No. 1 mean?

This is a Schedule 13G/A Amendment No. 1, a beneficial ownership report for holders above 5% using a passive or institutional framework. Amendment No. 1 indicates it updates a prior Schedule 13G, reflecting current ownership as of December 31, 2025.